Moderna's Options: A Look at What the Big Money is Thinking
Portfolio Pulse from Benzinga Insights
Deep-pocketed investors have shown a bullish sentiment towards Moderna (NASDAQ:MRNA), with options activity suggesting a price target between $70.0 and $160.0 in the next three months. Benzinga's tracking revealed 11 significant options activities, with a majority being bullish. The trading volume and open interest in Moderna's options have seen notable changes, indicating heightened investor interest. Moderna, a commercial-stage biotech, has its mRNA technology validated by the COVID-19 vaccine and is exploring various therapeutic areas.
February 14, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Significant options activity and bullish sentiment from major investors suggest a potential price movement for Moderna's stock in the short term, with a price target between $70 and $160.
The bullish sentiment among deep-pocketed investors, as indicated by the significant options activity, suggests a positive outlook for Moderna's stock price in the short term. The detailed options activity, including both calls and puts with a majority leaning bullish, alongside the current performance of Moderna's stock and its strategic position in the biotech industry, supports the anticipation of a potential price increase within the specified price target range.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100